Biomarin Pharmaceutical (BMRN) Free Cash Flow (2009 - 2026)

Biomarin Pharmaceutical has disclosed Free Cash Flow across 18 years of filings, most recently posting $199.7 million for Q1 2026.

• Quarterly Free Cash Flow rose 26.71% year-over-year to $199.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $767.1 million (up 22.89% YoY) and the FY2025 annual result came in at $725.0 million, up 48.73% from the prior year.
• Free Cash Flow grew to $199.7 million in Q1 2026, from $58.9 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $340.2 million in Q3 2025 and troughed at -$98.4 million in Q1 2023.
• A 5-year average of $90.0 million and a median of $97.4 million in 2024 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow sank 184.37% — and 2024, when it soared 11682.78%.
• Tracing BMRN's Free Cash Flow over 5 years: stood at -$28.9 million in 2022, then surged by 95.04% to -$1.4 million in 2023, then surged by 11682.78% to $166.1 million in 2024, then sank by 64.53% to $58.9 million in 2025, then surged by 238.97% to $199.7 million in 2026.
• Business Quant data shows BMRN's Free Cash Flow at $199.7 million in Q1 2026, $58.9 million in Q4 2025, and $340.2 million in Q3 2025.